The activities of Core C have expanded greatly in two ways. First, more and more allogeneic hematopoietic stem cell transplants are being carried out in the ambulatory clinic. Secondly, in the interest of accelerating accrual of patients with relatively rare non-malignant diseases and myelodysplastic/myeloproliferative disease syndromes, we have initiated a number of multi-center trials which are in large part coordinated by the staff in Core C. The first activity Core C provides includes determining eligibility, IRB assurances, registration, treatment, evaluation of patient outcomes and data collection during the ambulatory clinic phase of core within treatment, evaluation of patient outcomes and data collection during the ambulatory clinic phase within the first 3-4 months after transplantation at the FHCRC, and subsequent evaluation in the clinic by the staff of the Long-Term Follow-Up Core D during annual patient visits. The second activity of Core C supports coordination of data retrieval from collaborating institutions participating in the multi-center trials initiated outside the FHCRC covered in Projects 1 and 4. Beyond data collection, this collaboration requires feedback of data among participating institutions, and multi-center assurances of IRB requirements. Core C staff maintain a satellite database containing data from the multi-center studies which are combined with data from the central database for FHCRC patients. The staff in Core C works with the staff in Core B in the design of the satellite databases used to collect specialized data for non-malignant diagnoses and to collect data from other sites in collaborative studies. The personnel in Core C constitute a research nurse for the FHCRC ambulatory clinic, a data coordinator for conventional allogeneic transplantation trials in the FHCRC ambulatory clinic and multi-center collaborators on conventional allogeneic transplantation protocols, a data coordinator for the multi-center non- myeloablative allogeneic transplantation trials, and three physician investigators who evaluate patients in the clinic and conduct informed consent. The physician investigators are the core leader, a clinic physician investigator, and the physician investigator who leads the non- myeloablative transplantation weekly meeting, supervises the data coordinators and research nurse in the multi-center non-myeloablative clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL036444-21
Application #
6492860
Study Section
Project Start
1985-07-01
Project End
2006-07-31
Budget Start
Budget End
Support Year
21
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Thakar, M S; Bonfim, C; Walters, M C et al. (2017) Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia. Bone Marrow Transplant 52:570-573
Burroughs, Lauri M; Shimamura, Akiko; Talano, Julie-An et al. (2017) Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders. Biol Blood Marrow Transplant 23:1669-1677
Khera, Nandita; Gooley, Ted; Flowers, Mary E D et al. (2016) Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 22:1319-1323
Karoopongse, Ekapun; Marcondes, A Mario; Yeung, Cecilia et al. (2016) Disruption of Iron Regulation after Radiation and Donor Cell Infusion. Biol Blood Marrow Transplant 22:1173-1181
Hoffmeister, P A; Storer, B E; Syrjala, K L et al. (2016) Physician-diagnosed depression and suicides in pediatric hematopoietic cell transplant survivors with up to 40 years of follow-up. Bone Marrow Transplant 51:153-6
Gallo, S; Woolfrey, A E; Burroughs, L M et al. (2016) Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD? Bone Marrow Transplant 51:1573-1578
Festuccia, Moreno; Deeg, H Joachim; Gooley, Theodore A et al. (2016) Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. Biol Blood Marrow Transplant 22:1227-1233
Vaughn, J E; Anwer, F; Deeg, H J (2016) Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom? Vox Sang 110:5-11
Aki, S Z; Inamoto, Y; Carpenter, P A et al. (2016) Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity. Bone Marrow Transplant 51:1350-1353

Showing the most recent 10 out of 788 publications